The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Investigating higher teclistamab step-up dosing in R/R myeloma: results from MajesTEC-1
Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, comments on the potential benefits of using alternative teclistamab step-up dosing strategies in patients with relapsed/refractory (R/R) multiple myeloma (MM). Data from two cohorts of the MajesTEC-1 trial (NCT04557098) suggest that administering higher doses of teclistamab during the step-up dosing period may confine cases of cytokine release syndrome (CRS) to the step-up dosing period only, making physicians more comfortable with administering the agent. This could lead to increased adoption of teclistamab in clinical practice, but further studies are needed to confirm these findings. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
